Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 14/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31577284 | 0.84 | LRRK2 (0.41) | AOC3LRRK2 | |
| SCHEMBL29173530 | 0.80 | LRRK2 (0.37) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL30206129 | 0.80 | LRRK2 (0.37) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL31577363 | 0.77 | AOC3 (0.37) | AOC3KCNH2 | |
| SCHEMBL31577281 | 0.73 | RPS6KA5 (0.41) | MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL24944968 | 0.72 | SYK (0.35) | LRRK2ZAP70 | |
| SCHEMBL31577393 | 0.71 | TP53 (0.31) | AOC3 | |
| SCHEMBL29173596 | 0.70 | SYK (0.39) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL30206239 | 0.70 | SYK (0.39) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL31577303 | 0.70 | JAK2 (0.32) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |